No abstract available.
Albuterol* ; Humans ; Infant* ; Ultrasonics*

No abstract available.
Albuterol* ; Asthma* ; Gases* ; Inhalation*

To survey 30 patients aged 15-65 years with acute severe asthma. They were randomized into one of three different groups: group(A): reiceived salbutamol solution via a nebulizer impelled with oxygen; group (B): received Salbutamol solution via an air compressor-driven nebulizer; and group (C): received Salbutamol via a Metered-dose inhaler attached to a value aerosol holding chamber (Volumatic). After the 6 hours treatment, PEF (peak exhale flow) and other parameters improved significantly in 27 patients. No patient discontinued the trial or transferred to the intensive unit and no cardiovascular adverse events were reported in the study groups. These data showed that the three delivery methods were appropriate to treat subjects with acute severe asthma, however the metered dose inhaler (with holding chamber) was the best choice in the recent medical condition of Vietnam
Asthma ; Aerosols ; Albuterol ; Therapeutics ;

Background: Effect of salbutamol nebulization in the treatment of acute bronchiolitis in infants is contraverse. Objectives: This study aims to evaluate effect of salbutamol nebulization in infants with bronchiolitis. Subjects and method: Patients were divided into two groups. Treatment group was given salbutamol nebulization with dose of 0.15mg/kg/time, with 2ml sodium 0.9%, 2 times with 30 minute interval and control group. Indicators including Sa02, heart rate and respiratory rate were measured before and after nebuliser of salbutamol. These indicators were compared at times before nebulizing (T1) and after 15 minute (T2), 30 minute (T3), 60 minute (T4). Clinical trends and mean treatment days were compared between two groups. Results: There were 80 infants under 1 year old with bronchiolitis studied from July 2004 to July 2005. Of whom, there were 53 (66.3%) male and 27 (33.7) female. Mean age was 5.4 \xb1 2.69 months. There were 59 infants with mild and moderate forms and 21 infants with severe one. There were 47 infants treated by salbutamol nebulization and 33 infants in the control group. No significant difference of clinical trends and avarage treatment days were found between two groups. Conclusion: Salbutamol nebulization showed no effect on the treatment of acute bronchiolitis in infants.
Bronchiolitis/ therapy ; Albuterol/ diagnostic use

BACKGROUND AND OBJECTIVE: The knowledge about the effects of the nebulized B2-agonist on serum potassium is limited. We aimed to assess the possible hypokalemia following nebulization of salbutamol. METHOD: Seven patients(mean age 60 +- 7.1years) with acute exacerbated asthma were treated with salbutamol nebulization(5mg nebulization at 1 hour interval, 3 times) without concomitant use of steroid or other bronchodilator such as theophylline. RESULTS: There was a significant increase in FEV1, from 46.41+-25.91% at baseline to 62.86+-22.38% at 3 hours after treatment. Serum potassium concentration was significantly decreased, from 3.93+-0.58mEq/L at baseline to 3.41+-0.62mEq/L and 3.46+-0.53mEq/L at 1 hour and 3 hours after third nebulization, repectively. There was a significant prolongation of the QTc interval in EKG from 454.36+-27.07msec at baseline to 479.41+-35.64msec and 505.09+-58. 69msec at 1 hour and 3 hours after third nebulization, respectively. Serum salbutamol concentration was 4.18+-3.39ng/ml at baseline, and increased to 7.69+-6.94ng/ml and 9.84+10.34ng/ ml at 1 hour and 3 hours after treatment, respectively. Magnitude of the hypokalemia and the degree of prolongation of the electrocardiographic QTc interval were significantly correlated with the level of serum salbutamol concenturation. CONCLUSION: The results suggest that cardiac complication could develop due to hypokalemia during repeated salbutamol nebulization. Caution should be done in monitoring of serum potassium concentration when using nebulized salbutamol repeatedly for the treatment of acute exacerbated bronchial asthma.
Albuterol* ; Asthma ; Electrocardiography ; Hypokalemia ; Potassium* ; Theophylline

BACKGROUNDS: Assessment of the presence and degree of reversibility of airflow obstruction is clinically important in patients with asthma or chronic obstructive pulmonary disease. The measurement of peak expiratory flow(PEF) is a simple, fast, and cheap method to assess the severity of obstruction and its degree of reversibility. Assessing the reversibility of airflow obstruction by peak expiratory flow(PEF) measurements would be is practicable in general practice, but its usefulness has not been well investigated. We compared PEF and FEV1 in assessing reversibility of airflow obstruction in patients with chronic obstructive pulmonary disease or asthma and developed a practical criterion for assessing the presence of reversibility in general practice. METHODS: PEF measurements were performed (Spirometry) in 80 patients(aged 24-78) with a history of asthma or chronic obstructive lung disease before and after the inhalation of 200 mg salbutamol. The change in PEF was compared with the change in forced expiratory volume in one second(FEV1). Reversible airflow obstruction was analysed analyzed according to American Thoracic Society(ATS) criteria. RESULTS: When defined as a 12% A 12% increase above the prebronchodilator value and a 200ml increase in either FVC or FEV1 reversibility was were observed in 45%(36) of the patients. Relative operating characteristic(ROC) analysis showed that an absolute improvement in PEF of 30l/min gave optimal discrimination between patients with reversible and irreversible airflow obstruction(the sensitivity and specificity of an increase of 30l/min in detecting a 12% increase above the prebronchodilator value and a 200ml increase in either FVC or FEV1 were 72.2% and 72.7% respectively, with a positive predictive value of 68.4%) CONCLUSIONS: Absolute changes in PEF can be used to diagnose reversible airflow obstruction.
Albuterol ; Asthma ; Discrimination (Psychology) ; Forced Expiratory Volume ; General Practice ; Humans ; Inhalation ; Pulmonary Disease, Chronic Obstructive

Recently, some cases of paradoxical bronchoconsthction with the use of nebulized antiasthmatic respirator solutions have been reported. This study was performed to determine whether benzalkonium chloride, contained in several antiasthmatic respirator solutions as a preservative, may cause paradoxical bronchoconstriction. This was accomplished by comparing the FEV(1) change after Ventolin (benzalkonium containing salbutamol) nebulization with the FEV(1) change after Respolin autohaler (benzalkonium free sa1butamol) inhalation within the same patient. This study consisted thirty patients with stable asthma who regularly attend the allergy clinic at Wallace Memorial Baptist Hospital. Patients were excluded from the study if they had respiratory disease or were taking any other medications. The results are as knows: 1) The baseline FEV(1) in the Ventolin group was 73+/-1O(% predicted) and 74+/-10(% predicted) in the Respolin autohaler group, showing no statistical difference in baseline FEV(1) between the two groups. 2) FEV(1) was decreased in 9 subjects(3096) after Ventolin nebu1ization and in 1 subject(3396) after Respolin autohaler inhalation, showing that the incidence of FEV(1) fall was higher in the Vento1in group than in the Respo1in autohaler group(p<0.OO5, one-tailed t-test). 3) Considering the cases with increased FEV(1) after inhalation, FEVl was increased by 9+/-7 (% predicted) in the Vento1in group and 7+/-5(% predicted) in the Respolin autohaIer group, suggesting that bronchodi1ator effects of both medications are similar. 4) Mild coughing occurred in 4 subjects(13396), and mild chest tightness in 1 subject(33%) in the Ventolin group. These symptoms resolved without any treatment. No side effects were reported by subjects in the Respolin autohaler group. In conclusion, these results strongly suggest that the paradoxical bron-choconstriction occurring with nebulized antiasthmatic respirator solutions is due to the ingredient benzalkonium chloride. Therefore we recommend that a benzalkoniulm free salbutamol product should be used for asthmatic patients, or if a product such as Ventolin which contains benza1konium chloride must be used, we recommend that it should be administered cautiously.
Albuterol ; Asthma ; Benzalkonium Compounds* ; Bronchoconstriction* ; Cough ; Humans ; Hypersensitivity ; Incidence ; Inhalation ; Protestantism ; Thorax ; Ventilators, Mechanical*

BACKGROUND: Although there are improvements of clinical symtoms after bronchodilator inhalation in COPD patients, it has been noted that there was no increase of FEV1 in some cases. FEV1 did not reflect precisely the improvement of ventilatory mechanics after bronchodilator inhalation in these COPD patients. The main pathophysiology of COPD is obstruction of airway in expiratory phase but in result, the load of respiratory system is increased in inspiratory phase. Therefore the improvement of clinical symptoms after bronchodilator inhalation may be due to the decrease of inspiratory load. So we performed the study which investigated the effect of bronchodilator on inspiratory response of vetilatory mechanics in COPD patients. METHODS: In 17 stable COPD patients, inspiratory and expiratory forced flow-volume curves were measured respectively before bronchodilator inhalation. l0mg of salbutamol solution was inhaled via jet nebulizer for 4 minutes. Forced expiratory and inspiratory flow-volume curves were measured again 15 minutes after bronchodilator inhalation. RESULTS: FEV1, FVC and FEV1/FVC% were 0.92 +/-0.34L(38.3+/- 14.9% predicted), 2.5+/-0.81L (71.1 +/-21.0% predicted) and 43.1+/-14.5% respectively before bronchodilator inhalation. The values of increase of FEV1, FVC and PIF(Peak Inspiratory Flow) were 0.15 +/-0.13L(relative increase: 17.0%), 0.58+/-0.38 L(29.0%) and 1.0+/-0.56L/sec(37.5%) respectively after bronchodilator inhalation. The increase of PIF was twice more than FEV1 in average(p<0.001). The increase of PIF in these patients whose FEV1 was not increased after bronchodilator inhalation were 35.0%, 44.0% and 55.5% respectively. CONCLUSION: The inspiratory parameter reflected improvement of ventilatory mechanics by inhaled bronchodilater better than expiratory parameters in COPD patients.
Albuterol ; Humans ; Inhalation ; Mechanics ; Nebulizers and Vaporizers ; Pulmonary Disease, Chronic Obstructive* ; Respiratory System

PURPOSE: This study was preformed to demonstrate the improvement of respiratory symptoms and pulmonary function parameters after albuterol inhalation in asthmatic bronchitis using pneumotachography. METHODS: Fifteen asthmatic bronchitis patients admitted to Ewha Womans University Hospital from September in 1998 to July in 1999 were enrolled in this study. Clinical symptoms and pulmonary function parameters including respiratory rate, heart rate, inspiratory tidal volume(Vi), expiratory tidal volume(Ve), peak tidal expiratory flow(PTEF), tidal expiratory flow at 25% of tidal volume(TEF25), mid-expiratory flow(MEF) and mid-inspiratory flow(MIF), compliance, and pulmonary resistance were evaluated by clinical symptom score and pneumotachography before and after albuterol inhalation treatment. RESULTS: The clinical score was decreased significantly after treatment, but heart rate did not show a significant difference. By flow-volume curve, Ve were 7.39+/-2.11 mL/kg, 9.39+/-3.20 mL/kg, and Vi were 7.44+/-2.08 mL/kg, 9.46+/-3.26 mL/kg, and PTEF were 130.1+/-82.1 mL/kg, 123.1+/-64.8 mL/kg before and after treatment, respectively. All the pulmonary function parameters showed no significant differences before and after treatment. CONCLUSIONS: Clinical symptoms were improved after albuterol inhalation treatment in asthmatic bronchitis, but pulmonary function was not recovered after a short-term treatment.
Albuterol ; Bronchitis* ; Compliance ; Female ; Heart Rate ; Humans ; Inhalation ; Respiratory Function Tests* ; Respiratory Rate

PURPOSE: Nebulized selective beta2-adrenoreceptor agonists have been widely used in acute asthma and selectively in acute bronchiolitis. However, nebulized salbutamol have been reported to cause arterial oxygen desaturation in some of the acute bronchiolitis and severe asthma patients. This may be the results of a paradoxical bronchoconstriction linked to acidic and hyper-osmolar nebulized salbutamol solution and etc. We assessed the changes in arterial oxygen saturation by percutaneous pulse oxymeter during and after nebulization of salbutamol solution and compared the effect of 100% oxygen with the compressed air as a driving gas. METHODS: This study was performed in 80 mild to moderate wheezy children(bronchiolitis 51, asthma 29) who were admitted to Pediatrics department of of EWHA from January 1992 to October 1993. The study children are randomly assigned to be nebulized by compressed air or 6l/min of 100% oxygen as a driving gas. The arterial oxygen saturation, wheeze score, retraction score, and heart rate were recorded before nebulization, post-nebulization, 5, 10, 15 and 30minutes. RESULTS: 1) Arterial oxygen saturation decreased significantly at post-nebulization five minutes only in bronchiolitis, treated with salbutamol nebulization without oxygen(p<0.01). Salbutamol nebulization, with oxygen (6l/min) has not changed arterial oxygen saturation both in bronchiolitis and asthma(p>0.05). 2) Wheeze score decreased significantly at post-nebulization 5-30minutes in asthma but not in bronchiolitis whether nebulized salbutamol with or without oxygen(p<0.05). 3) Retraction score increased significantly at post-nebulization 0-5minutes or unchanged in bronchiolitis but significantly decreased in asthma at 10-30minutes(p<0.05). 4) There were no significant change in heart rate and respiratory rate in both groups(p>0.05). CONCLUSIONS: Significant fall in arterial oxygen saturation was noted only in bronchiolitis treated with salbutamol nebulization without oxygen. In bronchiolitis, oxygen (6l/min) is better than compressed air as a driving gas during salbutamol nebulization to prevent hypoxemia.
Albuterol* ; Anoxia ; Asthma ; Bronchiolitis ; Bronchoconstriction ; Child* ; Compressed Air ; Heart Rate ; Humans ; Infant* ; Oxygen* ; Pediatrics ; Respiratory Rate